Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SuperGen rises 8.8% on US FDA acceptance of Dacogen sNDA in AML

This article was originally published in Scrip

Executive Summary

SuperGen jumped as high as 8.8%, or 26 cents, on 13 July on the news that the US FDA accepted for review the supplemental new drug application (sNDA) for Dacogen (decitabine) as a treatment for acute myeloid leukemia (AML), a life-threatening hematological cancer for which there are few treatment options.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts